Idera Pharmaceuticals Inc. (toll-like receptor (TLR) antagonists for autoimmune diseases and B-cell lymphomas) signed on Abbott Laboratories Inc. to develop a companion in vitro diagnostic for use with its Phase II IMO8400 B-cell lymphoma program. (May)
The Big Pharma will apply polymerase chain reaction (PCR) technology to detect, with high sensitivity and specificity, the MYD88 L265P...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?